Kalvista Pharmaceuticals Inc

NASDAQ KALV

Download Data

Kalvista Pharmaceuticals Inc Retained Earnings To Equity Ratio 1 year YoY Change (%) for the year ending April 30, 2023: -57.63%

Kalvista Pharmaceuticals Inc Retained Earnings To Equity Ratio 1 year YoY Change (%) is -57.63% for the year ending April 30, 2023, a 46.20% change year over year. The retained earnings to equity ratio measures the proportion of a company's retained earnings to its shareholders' equity. It is calculated by dividing the retained earnings by the shareholders' equity. This ratio provides insights into the company's reinvestment of earnings and the level of retained profits relative to shareholders' equity. A higher ratio suggests a higher proportion of earnings being retained for reinvestment or future distribution to shareholders. The measure "Change (%)" refers to the percentage change in the value of a financial metric between two time points. This measure provides a relative perspective on the magnitude of change.
  • Kalvista Pharmaceuticals Inc Retained Earnings To Equity Ratio for the year ending April 30, 2022 was -1.35, a -107.12% change year over year.
  • Kalvista Pharmaceuticals Inc Retained Earnings To Equity Ratio for the year ending April 30, 2021 was -0.65, a 55.05% change year over year.
  • Kalvista Pharmaceuticals Inc Retained Earnings To Equity Ratio for the year ending April 30, 2020 was -1.45, a -51.87% change year over year.
  • Kalvista Pharmaceuticals Inc Retained Earnings To Equity Ratio for the year ending April 30, 2019 was -0.96, a 63.64% change year over year.
NASDAQ: KALV

Kalvista Pharmaceuticals Inc

CEO Mr. Thomas Andrew Crockett M.B.A.
IPO Date April 9, 2015
Location United States
Headquarters 55 Cambridge Parkway, Cambridge, MA, United States, 02142
Employees 118
Sector Healthcare
Industry Biotechnology
Description

KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with unmet needs in the United States. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include sebetralstat, which is initiation of the Phase 3 KONFIDENT trial as a potential oral, on-demand therapy for HAE attacks; and Factor XIIa, an oral inhibitor program which is in preclinical stage targets an enzyme in HAE. The company is headquartered in Cambridge, Massachusetts.

Similar companies

THRX

Theseus Pharmaceuticals Inc

NA

NA

KURA

Kura Oncology Inc

NA

NA

REPL

Replimune Group Inc

NA

NA

COGT

Cogent Biosciences Inc

NA

NA

CGEM

Cullinan Oncology LLC

NA

NA

EWTX

Edgewise Therapeutics Inc

NA

NA

StockViz Staff

September 20, 2024

Any question? Send us an email